72 results about "Cell Surface Proteins" patented technology

Provided herein are novel stabiligases for use in cell membrane proteome analysis. The subject stabiligases are capable of attaching to glycans found on the surface of cell membranes to form glycan-tethered (GT) stabiligases. Such glycan-tethered stabiligases are capable of robustly and selectively attaching label probes to cell surface proteins of intact cells. The subject novel stabiligases described herein advantageously allow for the identification and profiling of cell membrane proteins that have undergone an extracellular N-terminal proteolytic event.

Provided are compositions containing a conjugate containing a phthalocyanine dye, including compositions containing stabilizing agents, such as non-ionic surfactants and / or protectants. In some aspects, the compositions result reduced aggregation of the conjugate due to agitation, temperature exposure, and / or pH. Also provided are articles of manufacture containing the compositions containing the conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the phthalocyanine dye conjugates are conjugated to a targeting molecule, such as an antibody, that targets the conjugate to a cell or pathogen, such as by binding to a cell surface protein.

Provided are methods for manufacturing a conjugate containing a phthalocyanine dye, including methods that include one or more steps of preparing or producing the conjugate, formulating the conjugate and packaging the conjugate. In some aspects, the manufacturing methods result in the generation of a stable conjugate. Also provided are stable phthalocyanine dye conjugates, compositions and articles of manufacture containing the stable conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the phthalocyanine dye conjugates are conjugated to a targeting molecule, such as an antibody, that targets the conjugate to a cell or pathogen, such as by binding to a cell surface protein.

CD318 (CDCP1) is a CUB-domain containing cell surface protein over-expressed in major types of cancers to promote tumor growth and metastasis. The present disclosure relates to the identification and characterization of novel anti-CD318 monoclonal antibodies. By targeting CD318 as a tumor associated antigen, the disclosure further relates to different modalities of using anti-CD318 antibodies to kill cancer cells, including CD318 antibody based immunocytokines, CD318 antibody-based immune modulators, and CD318 antibody drug conjugates.

The invention relates to the technical field of cell analysis, and discloses a cell analysis method, a cell analysis device and a storage medium, and the method comprises the following steps: S1, multi-modal labeling: synchronously loading cell surface protein, a metabolism probe and a spatial positioning marker; s2, collaborative acquisition: obtaining space-time multi-dimensional data through flow type, mass spectrum and two-photon combination; s3, tensor modeling: constructing four-dimensional data and correcting spatial drift; s4, metabolic constraint decomposition: executing non-negative tensor decomposition to obtain a factor matrix; s5, dynamically adjusting parameters: optimizing excitation and sampling frequencies in real time according to factor changes; and S6, feature analysis: calculating a metabolism-phenotype coupling index. Through a multi-modal synchronous marking and four-dimensional dynamic tensor modeling method, cross-dimensional association of physical characteristics, molecular expression and metabolic activity is broken through, lossless fusion of single-cell multi-dimensional data is realized, and the spatial resolution is greatly improved compared with the prior art.

The present invention provides a dual DNA tetrahedron structure, a preparation method and an application thereof. The dual DNA tetrahedron of the present invention includes a first DNA tetrahedron structure, a second DNA tetrahedron structure and a connecting chain. This structure can specifically recognize two cell surface proteins and be labeled by fluorescence; at the same time, due to the steric hindrance effect of the structure, it is difficult for the two proteins to approach each other, affecting the interaction between the two. This structure can exist on the cell surface for a long time, thus having a good cell regulation effect on these two cell membrane surface proteins, specifically reflected in reducing the phosphorylation level of HER2 protein, promoting the expression of apoptosis-related proteins, and ultimately leading to apoptosis of tumor cells and reducing the cell activity of tumor cells.

Genetically engineered cells (e.g., HSPCs or T cells) having one or more genetically edited cell surface protein genes, such as hematopoietic stem cells, and therapeutic uses thereof, alone or in combination with immunotherapy targeting the cell surface proteins.

The invention provides a three-specificity immune cell adapter-cytokine fusion protein for malignant tumor immunotherapy as well as a preparation method and application of the three-specificity immune cell adapter-cytokine fusion protein. The fusion protein comprises a first binding domain, a second binding domain and a cytokine structural domain which are covalently linked to form a single polypeptide chain or polypeptide compound. The first binding domain is specifically bound with a tumor associated antigen, and the target spot of the first binding domain comprises but is not limited to KK-LC-1, MSLN, HER2, Claudin18.2, Claudin6 and PSMA; the second binding domain is specifically bound with a CD3 protein complex on the surface of the T cell; the cytokine domain is IL2, IL15, IL12, IL21 or a functional variant thereof. The invention also relates to a nucleic acid molecule for coding the fusion protein, an expression vector and application thereof. The fusion protein can be used for immunotherapy of malignant tumors such as colon cancer, gastric cancer, breast cancer, liver cancer, lung cancer and cervical cancer, and has a good application prospect. The invention effectively solves the problems of insufficient T cell activation and limited killing in solid tumor immunotherapy in the prior art.

Methods, compositions, and systems for treating various cancers are disclosed. The disclosed compositions may include a poly peptide with affinity for a CD99 cell surface protein. Disclosed polypeptides may comprise a sequence selected from GYYMH, RINPYTGATTYNQIFKD, YYYGNNYNVYLDY, SASQGISNYLS, YTSTLHIS, and QQYSNLPWT, and may include mouse, human, or humanized peptide sequences. In many embodiments, the polypeptides may be immunoglobulins, for example IgG3 or IgG4. The disclosed polypeptides may be administered to a subject having a cancer cell with elevated expression of CD99. In some embodiments, the subject may be suffering from cancer, including diffuse intrinsic pontine glioma (DIPG). Ewing Sarcoma, acute myeloid leukemia (AML), ependymoma, or neuroblastoma. Treatment methods include administering the disclosed polypeptides to a subject that may also be treated with radiation. Disclosed herein are systems for treating one or more cancers. The systems may comprise a radiation source, for example a medical fractionated radiation source.

The present application relates to a compositions and methods comprising or expressing a hevamine A-related MoMo30 protein from Momordica balsamina. The MoMo30 protein is about 30 kDa in size, is stable after being autoclaved at 120° C. for 30 min, resists proteolytic cleavage by trypsin, exhibits mannose-sensitive binding to HIV gp120, exhibits hemagglutinin and chitinase activity, is capable of activating and stimulating T cell proliferation, is capable of preventing infection by HIV-1 or alleviating symptoms in an HIV-1 infected patients, and comprises an amino acid sequence of SEQ ID NO: 4. The MoMo30 protein and / or a nucleic acid encoding the same may be used in methods for preventing or treating microbial infections by HIV, SARS-CoV-2 and other enveloped viruses, as well as other microorganisms comprising cell surface proteins containing glycan residues, such as mannose.

Disclosed herein are immune cells (Bisuper Cells, BS-Cells) that have been engineered to express an immune cell activator polypeptide comprising an extracellular marker domain and incorporate the polypeptide into the cell membrane surface. Also disclosed are immune cells engineered to secrete one or more polypeptide effector molecules, and immune cells engineered to express both molecules. Nucleic acid vectors for expressing these molecules in immune cells are disclosed. Also disclosed are bispecific polypeptides that can be used to specifically bind immune cells expressing immune cell activator polypeptides to another cell. Also disclosed are systems comprising both immune cells and various bispecific polypeptides that can bind to different cell surface proteins of the same or different target cells, e.g., that can be used to expand immune cells in vivo and treat various tumors.

The present invention relates to a computer-implemented method for obtaining, by training, a tuned model configured to predict whether a protein is present at least partially on the external surface of a cell, a computer-implemented method for determining whether a protein is at least partially present on the external surface of a cell, a computer-implemented method for forming a dataset for obtaining, by training, the tuned model, and a system comprising a processor coupled to a memory and preferably a graphical user interface, the memory having recorded thereon the computer program comprising instructions for performing any of the computer-implemented methods.

The present invention relates to NK cells expressing dual-targeting chimeric antigen receptors for CD19 and CD22, and uses thereof. In the present invention, it was found that the delivery efficiency of a CAR expression vector and the production efficiency of CAR-NK cells are excellent when, among the cell surface proteins of PBMCs for producing CAR-NK cells (UCI-101), CD16 is expressed at 70% or less, natural killer group 2D (NKG2D) is expressed at less than 10%, CD57 is expressed at 30% or less, low-density lipoprotein receptor (LDLR) is expressed at 0.1% or more, and natural cytotoxicity triggering receptor 3 (NKp30) is expressed at less than 10%. In addition, optimal conditions for inducing NK cell differentiation and optimal conditions for transduction, under which the delivery efficiency of a CAR expression vector and the production efficiency of CAR-NK cells are excellent, were established, and CAR-NK cells produced by the method according to the present invention were found to exhibit an excellent antitumor effect in an animal model, and thus can be effectively used as a composition for preventing or treating diseases related to CD22 (or CD19) expression or diseases related to B cells.

The present disclosure provides methods and compositions for modulating cell surface proteins and receptor complexes using a novel class of glycan conjugates that can be used to engage the signaling pathways within desired cell types. Such defined cell-targeting bioactive glyco-ligands are directed for cell engagement and activation in therapeutic applications.

A rapid detection method for cytotoxic T cells in peripheral blood. The method enables rapid identification of cytotoxic T cells in peripheral blood by detecting the expression of T-cell surface protein CX3CR1, or CX3CR1 and GPR56. The detection method is rapid in operation, does not involve cell fixation and permeabilization, and does not affect cell activity.

Provided herein are methods for generating a mass spectrometry (MS) profile of a sample from a cell composition, such as an engineered cell composition. In some embodiments, the mass spectrometry profile includes data based on one or more mass spectrometry analyses or techniques. Also provided herein are methods for, based on mass spectrometry profiles of one or more samples of such cell compositions: identifying a mass spectrometry (MS) profile of a genetically engineered cell composition comprising immune cells comprising a recombinant receptor by comparison to a reference mass spectrometry profile; characterizing a process for producing genetically engineered cell composition; assessing cell surface proteins of an engineered cell composition; and assessing a process for producing a genetically engineered cell composition.

The application relates to preparation and application of anti-CD38 rabbit recombinant monoclonal antibodies, the obtained antibodies have good specificity, most importantly, the antibodies have high affinity and can recognize natural cell surface CD38 proteins, and can be used for flow, ELISA and immunohistochemical detection applications.

Provided is a novel compound useful for, e.g., comprehensive analysis of cell surface proteins. Disclosed is a functional compound or a salt thereof in which a tyrosine residue reaction site R is linked to a protein purification tag site Tag via a spacer S. The tyrosine residue reaction site R is a group represented by formula (1). (In the formula, * denotes a bond with a spacer S, and R1 and R2 are each independently selected from the group consisting of H, alkyl which optionally be substituted with one or more substituents, aryl which optionally be substituted with one or more substituents, and heteroaryl which optionally be substituted with one or more substituents.)

The present invention provides a nano-antibody targeting CD38, a pharmaceutical composition, and its application, relating to the field of biomedicine technology. The nano-antibody targeting CD38 is any one of a first antibody and a second antibody, and both include three complementary determining regions; the sequences of the complementary determining regions CDR1 to 3 of the first antibody are shown in SEQ.ID NO.1, SEQ.ID NO.3, and SEQ.ID NO.5; the sequences of the complementary determining regions CDR1 to 3 of the second antibody are shown in SEQ.ID NO.2, SEQ.ID NO.4, and SEQ.ID NO.6. The nano-antibody has a high affinity for both purified and cell surface CD38 proteins, providing an effective new method for targeting CD38 for anti-tumor intervention; and molecular probes and other detection reagents can be prepared based on the nano-antibody, providing a new approach for tumor-specific imaging and diagnosis by specifically binding to CD38 on the tumor surface.

This invention relates to ligand exchange proteins comprising the luminal domain of TAP-binding protein-related (TAPBPR), which functions as a MHC class I ligand-exchange catalyst when presented to mammalian cells either as a soluble extracellular protein or as a membrane bound cell surface protein. This may be useful in modulating immune responses, including for example loading immunogenic ligand onto tumors or other disease cells to induce their recognition by T cells. Ligand-exchange proteins and methods for their use are provided. The invention further relates to an approach for generating conditional peptide ligands for a range of disease-related MHC-I allotypes. The present invention relates to chicken and human TAPBPRs and tapasins as well as orthologs thereof, derivatives thereof, and any mutants thereof as well as any combinations thereof. The present invention also relates to placeholder conditional ligands for ligand-exchange reactions across multiple HLA allotypes.

The present invention relates to a genetically engineered protein comprising: at least one binding domain which is capable of binding to a cell surface protein on an avian antigen presenting cell; and a) at least one antigenic polypeptide orb) at least one binding domain which is capable of binding to at least one antigenic polypeptide. The present invention also relates to avian vaccines comprising at least one binding domain which is capable of binding to a cell surface protein on an avian antigen presenting cell; and a) at least one antigenic polypeptide or b) at least one binding domain which is capable of binding to at least one antigenic polypeptide and to the use of such vaccines to treat and / or prevent disease in avian subjects.

The present disclosure provides methods and compositions for using a novel class of glycan conjugates for modulating cell surface proteins and receptor complexes that can be used to engage signaling pathways within desired cell types. Such defined cell-targeting bioactive glycoligands are directed to cell engagement and activation in therapeutic applications.

The present invention features compositions and methods for conditioning a patient (e.g., to promote transplantation and / or implantation). The invention provides a base editing strategy for targeting a cell surface protein. The strategy can be used for conditioning.

Genetically engineered cells (e.g., HSPCs or T cells), such as hematopoietic stem cells, having one or more genetically edited genes of cell-surface proteins, and therapeutic uses thereof, either alone or in combination with immune therapy that targets the cell-surface protein(s).

Viral particles for activating and transducing immune cells in vitro or in vivo, as well as compositions and methods for using said viral particles are provided. The present disclosure is based, at least in part, on the discovery that viral particles can be produced such that a cell surface protein is expressed on the viral envelope to simultaneously prime and transduce immune cells. In particular, as demonstrated herein, viral particles expressing a TCR targeting molecule and a costimulatory molecule enhance cell activation in vivo and transduction of nucleotides encoding a polypeptide of interest as compared to viral particles expressing only the TCR targeting molecule.

The present invention provides a kind of thermosensitive cell microcarrier and preparation method thereof, and the method for culturing cells. The preparation method provided by the present invention, using glass microspheres as basic materials to carry out surface hydroxylation, then aminosilane coupling agent is used to carry out amino modification, then the N-carboxylic acid anhydride (NCA) of glutamic acid modified by propargyl alcohol is polymerized on the surface of glass microspheres, and finally click chemistry reaction is carried out with azido oligoethylene glycol to obtain a surface-covered thermosensitive polymer glass microsphere with good cell compatibility. The thermosensitive cell microcarrier prepared by the present invention has extremely low cytotoxicity and good biosafety; moreover, it has thermosensitive performance, can achieve efficient cell adhesion and detachment, and effectively detaches cells in a low temperature environment; when it is used as a carrier to culture cells, three-dimensional space is provided to cell growth, and compared with a two-dimensional plane, cell amplification can be achieved, the cost of cell culture is reduced, and the effect of protecting cell surface proteins is possessed.

The invention discloses an activated one-step covalent labeling fluorescent probe and application thereof, and belongs to the field of organic chemistry, and the activated fluorescent probe CAZ-ONBD provided by the invention can realize one-step turn-on covalent labeling and no-clean imaging of cell surface whole membrane protein in a simple, convenient and effective manner. Due to the interaction between the CAZ and the phospholipid bilayer, the CAZ-ONBD can be spontaneously inserted into a cell membrane. Then, the CAZ-ONBD can be subjected to nucleophilic substitution reaction with free amino groups of proteins adjacent to the cell surface, and enhancement of fluorescence signals can be realized while membrane proteins are covalently labeled. Experimental results show that the CAZ-ONBD can realize about 25 times of fluorescence signal enhancement in vitro, and allows quick labeling and imaging of the whole membrane protein on the surface of the living cell. The micromolecular fluorescent probe is the first micromolecular fluorescent probe for realizing one-step covalent labeling and no-clean imaging on the whole membrane protein on the cell surface.

The application provides a method for separating and purifying cell surface proteins and application thereof. The method comprises the following steps: culturing cells to be separated, adding an azide solution to the cells for incubation, then adding a Tris-HCl buffer to terminate the reaction, so as to label the cell surface proteins with azides; then adding a TNTE buffer and a protease inhibitor to lyse the cells, centrifuging to obtain cell lysates labeled with azides; incubating the cell lysates labeled with azides with phosphine-biotin-streptavidin magnetic beads, so as to enrich the cell surface proteins labeled with azides, and obtain magnetic beads containing the cell surface proteins. The method can effectively separate the cell surface proteins, has low background, high efficiency and good repeatability, and can be applied to quantitative analysis of cell surface proteomes.

Provided are compositions containing a conjugate containing a phthalocyanine dye, including compositions containing stabilizing agents, such as non-ionic surfactants and / or protectants. In some aspects, the compositions result reduced aggregation of the conjugate due to agitation, temperature exposure, and / or pH. Also provided are articles of manufacture containing the compositions containing the conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the phthalocyanine dye conjugates are conjugated to a targeting molecule, such as an antibody, that targets the conjugate to a cell or pathogen, such as by binding to a cell surface protein.

A transkingdom platform for the delivery of therapeutics to target cells. The system maintains the export and uptake functions of Inv while modifying its targeting away from β1 integrin to other proteins expressed on the surface of target eukaryotic cells (i.e., a cell surface protein) or chemical moieties (i.e., a cell surface chemical moiety) expressed on the surface of a target eukaryotic cell by replacing D4 and D5 of Inv with a binding domain from a heterologous protein via genetic engineering. These heterologous proteins could be derived from bacterial, fungal, animal, or viral genomes. This engineering would result in the construction of a chimeric Inv protein in which D1-D3 (i.e., the non-binding domains) are fused in frame to an alternative binding domain derived from a heterologous protein. The alternative binding domain would interact with a different cell surface protein or chemical moiety, which can in some instances be referred to as a receptor, on the surface on the surface of a eukaryotic cell, thereby allowing specific targeting to cells independent of Inv's intrinsic β1 integrin binding.